Ruxolitinib Phosphate Patent Expiration
Ruxolitinib Phosphate is used for treating conditions such as myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease. It was first introduced by Incyte Corp
Ruxolitinib Phosphate Patents
Given below is the list of patents protecting Ruxolitinib Phosphate, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Opzelura | US11602536 | Topical treatment of vitiligo by a JAK inhibitor | May 05, 2041 | Incyte Corp |
| Opzelura | US11510923 | Ruxolitinib formulation for reduction of itch in atopic dermatitis | Sep 04, 2040 | Incyte Corp |
| Opzelura | US11590137 | Ruxolitinib formulation for reduction of itch in atopic dermatitis | Sep 04, 2040 | Incyte Corp |
| Opzelura | US12589096 | Ruxolitinib Formulation For Reduction Of Itch In Atopic Dermatitis | Sep 04, 2040 | Incyte Corp |
| Opzelura | US12233067 | Topical treatment of vitiligo by a JAK inhibitor | Jul 28, 2040 | Incyte Corp |
| Opzelura | US11590138 | Topical treatment of vitiligo by a jak inhibitor | Jun 10, 2040 | Incyte Corp |
| Jakafi Xr |
US11337927 (Pediatric) | Sustained-Release Dosage Forms Of Ruxolitinib | Jul 17, 2034 | Incyte Corp |
| Jakafi Xr |
US10874616 (Pediatric) | Sustained-Release Dosage Forms Of Ruxolitinib | May 14, 2034 | Incyte Corp |
| Jakafi Xr |
US11576864 (Pediatric) | Sustained-Release Dosage Forms Of Ruxolitinib | May 14, 2034 | Incyte Corp |
| Jakafi Xr |
US11576865 (Pediatric) | Sustained-Release Dosage Forms Of Ruxolitinib | May 14, 2034 | Incyte Corp |
| Jakafi Xr |
US11896717 (Pediatric) | Sustained-Release Dosage Forms Of Ruxolitinib | May 14, 2034 | Incyte Corp |
| Jakafi Xr | US11337927 | Sustained-Release Dosage Forms Of Ruxolitinib | Jan 17, 2034 | Incyte Corp |
| Jakafi Xr | US10874616 | Sustained-Release Dosage Forms Of Ruxolitinib | Nov 14, 2033 | Incyte Corp |
| Jakafi Xr | US11576864 | Sustained-Release Dosage Forms Of Ruxolitinib | Nov 14, 2033 | Incyte Corp |
| Jakafi Xr | US11576865 | Sustained-Release Dosage Forms Of Ruxolitinib | Nov 14, 2033 | Incyte Corp |
| Jakafi Xr | US11896717 | Sustained-Release Dosage Forms Of Ruxolitinib | Nov 14, 2033 | Incyte Corp |
| Opzelura |
US10758543 (Pediatric) | Topical formulation for a JAK inhibitor | Nov 20, 2031 | Incyte Corp |
| Opzelura |
US10869870 (Pediatric) | Topical formulation for a JAK inhibitor | Nov 20, 2031 | Incyte Corp |
| Opzelura |
US11219624 (Pediatric) | Topical formulation for a JAK inhibitor | Nov 20, 2031 | Incyte Corp |
| Opzelura | US10758543 | Topical formulation for a JAK inhibitor | May 20, 2031 | Incyte Corp |
| Opzelura | US10869870 | Topical formulation for a JAK inhibitor | May 20, 2031 | Incyte Corp |
| Opzelura | US11219624 | Topical formulation for a JAK inhibitor | May 20, 2031 | Incyte Corp |
| Opzelura | US11571425 | Topical formulation for a JAK inhibitor | May 20, 2031 | Incyte Corp |
| Opzelura | US11590136 | Topical formulation for a JAK inhibitor | May 20, 2031 | Incyte Corp |
| Opzelura | US12226419 | Topical formulation for a JAK inhibitor | May 20, 2031 | Incyte Corp |
| Opzelura | US12544381 | Topical Formulation For Jak Inhibitor | May 20, 2031 | Incyte Corp |
| Opzelura | US12564593 | Topical Formulation For A Jak Inhibitor | May 20, 2031 | Incyte Corp |
| Jakafi |
US10016429 (Pediatric) | Salts of the janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile | Dec 12, 2028 | Incyte Corp |
| Jakafi |
US8722693 (Pediatric) | Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile | Dec 12, 2028 | Incyte Corp |
| Jakafi |
US8822481 (Pediatric) | Salts of the janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d] pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile | Dec 12, 2028 | Incyte Corp |
| Jakafi |
US8829013 (Pediatric) | Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile | Dec 12, 2028 | Incyte Corp |
| Jakafi Xr |
US10016429 (Pediatric) | Salts of the janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile | Dec 12, 2028 | Incyte Corp |
| Jakafi Xr |
US11213528 (Pediatric) | Salts Of The Janus Kinase Inhibitor (R)-3-(4-(7H-Pyrrolo[2,3-D]Pyrimidin-4-Yl)-1H-Pyrazol-1-Yl)-3-Cyclopentylpropanenitrile | Dec 12, 2028 | Incyte Corp |
| Jakafi Xr |
US8722693 (Pediatric) | Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile | Dec 12, 2028 | Incyte Corp |
| Jakafi Xr |
US8822481 (Pediatric) | Salts of the janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d] pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile | Dec 12, 2028 | Incyte Corp |
| Jakafi Xr |
US8829013 (Pediatric) | Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile | Dec 12, 2028 | Incyte Corp |
| Opzelura |
US10610530 (Pediatric) | Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile | Dec 12, 2028 | Incyte Corp |
| Opzelura |
US8722693 (Pediatric) | Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile | Dec 12, 2028 | Incyte Corp |
| Opzelura |
US8822481 (Pediatric) | Salts of the janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d] pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile | Dec 12, 2028 | Incyte Corp |
| Jakafi |
US7598257 (Pediatric) | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors | Jun 24, 2028 | Incyte Corp |
| Jakafi |
US8415362 (Pediatric) | Pyrazolyl substituted pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | Jun 24, 2028 | Incyte Corp |
| Jakafi Xr |
US7598257 (Pediatric) | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors | Jun 24, 2028 | Incyte Corp |
| Jakafi Xr |
US8415362 (Pediatric) | Pyrazolyl substituted pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | Jun 24, 2028 | Incyte Corp |
| Opzelura |
US7598257 (Pediatric) | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors | Jun 24, 2028 | Incyte Corp |
| Opzelura |
US8415362 (Pediatric) | Pyrazolyl substituted pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | Jun 24, 2028 | Incyte Corp |
| Jakafi | US10016429 | Salts of the janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile | Jun 12, 2028 | Incyte Corp |
| Jakafi | US8722693 | Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile | Jun 12, 2028 | Incyte Corp |
| Jakafi | US8822481 | Salts of the janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d] pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile | Jun 12, 2028 | Incyte Corp |
| Jakafi | US8829013 | Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile | Jun 12, 2028 | Incyte Corp |
| Jakafi Xr | US10016429 | Salts of the janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile | Jun 12, 2028 | Incyte Corp |
| Jakafi Xr | US11213528 | Salts Of The Janus Kinase Inhibitor (R)-3-(4-(7H-Pyrrolo[2,3-D]Pyrimidin-4-Yl)-1H-Pyrazol-1-Yl)-3-Cyclopentylpropanenitrile | Jun 12, 2028 | Incyte Corp |
| Jakafi Xr | US8722693 | Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile | Jun 12, 2028 | Incyte Corp |
| Jakafi Xr | US8822481 | Salts of the janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d] pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile | Jun 12, 2028 | Incyte Corp |
| Jakafi Xr | US8829013 | Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile | Jun 12, 2028 | Incyte Corp |
| Opzelura | US10610530 | Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile | Jun 12, 2028 | Incyte Corp |
| Opzelura | US8722693 | Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile | Jun 12, 2028 | Incyte Corp |
| Opzelura | US8822481 | Salts of the janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d] pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile | Jun 12, 2028 | Incyte Corp |
| Jakafi | US7598257 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors | Dec 24, 2027 | Incyte Corp |
| Jakafi | US8415362 | Pyrazolyl substituted pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | Dec 24, 2027 | Incyte Corp |
| Jakafi Xr | US7598257 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors | Dec 24, 2027 | Incyte Corp |
| Jakafi Xr | US8415362 | Pyrazolyl substituted pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | Dec 24, 2027 | Incyte Corp |
| Opzelura | US7598257 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors | Dec 24, 2027 | Incyte Corp |
| Opzelura | US8415362 | Pyrazolyl substituted pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | Dec 24, 2027 | Incyte Corp |
| Jakafi |
US9079912 (Pediatric) | Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as Janus kinase inhibitors | Jun 12, 2027 | Incyte Corp |
| Jakafi |
US9814722 (Pediatric) | Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as janus kinase inhibitors | Jun 12, 2027 | Incyte Corp |
| Opzelura |
US10639310 (Pediatric) | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | Jun 12, 2027 | Incyte Corp |
| Opzelura |
US9079912 (Pediatric) | Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as Janus kinase inhibitors | Jun 12, 2027 | Incyte Corp |
| Opzelura |
US9974790 (Pediatric) | Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as janus kinase inhibitors | Jun 12, 2027 | Incyte Corp |
| Jakafi | US9079912 | Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as Janus kinase inhibitors | Dec 12, 2026 | Incyte Corp |
| Jakafi | US9662335 | Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as janus kinase inhibitors | Dec 12, 2026 | Incyte Corp |
| Jakafi | US9814722 | Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as janus kinase inhibitors | Dec 12, 2026 | Incyte Corp |
| Jakafi Xr | US11744832 | Heteroaryl Substituted Pyrrolo[2,3-B]Pyridines And Pyrrolo[2,3-B]Pyrimidines As Janus Kinase Inhibitors | Dec 12, 2026 | Incyte Corp |
| Jakafi Xr | US8530485 | Heteroaryl Substituted Pyrrolo[2,3-B]Pyridines And Pyrrolo[2,3-B]Pyrimidines As Janus Kinase Inhibitors | Dec 12, 2026 | Incyte Corp |
| Jakafi Xr | US9079912 | Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as Janus kinase inhibitors | Dec 12, 2026 | Incyte Corp |
| Jakafi Xr | US9206187 | Heteroaryl Substituted Pyrrolo[2,3-B] Pyridines And Pyrrolo[2,3-B] Pyrimidines As Janus Kinase | Dec 12, 2026 | Incyte Corp |
| Jakafi Xr | US9814722 | Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as janus kinase inhibitors | Dec 12, 2026 | Incyte Corp |
| Opzelura | US10639310 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | Dec 12, 2026 | Incyte Corp |
| Opzelura | US9079912 | Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as Janus kinase inhibitors | Dec 12, 2026 | Incyte Corp |
| Opzelura | US9974790 | Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as janus kinase inhibitors | Dec 12, 2026 | Incyte Corp |
Ruxolitinib Phosphate's Family Patents
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List
Clinical Trials
Recent Clinical Trials on Ruxolitinib Phosphate:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
